Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704431 · ClinicalTrials.gov registry record · Phase 1
A Study With Darapladib to Collect Tolerability Information
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00704431 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2 participants.
The verdict
NCT00704431, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and the remaining 9 days of dosing will occur at home. Subjects will record any adverse events throughout the dosing period in a paper diary. Subjects will return to the CRU 10-14 days after the last dose of darapladib for a follow-up visit. The total study duration for each subject including the screening, treatment and follow-up periods will be approximately 4 weeks.
Interventions
- DRUG SB-480848 (darapladib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704431
The ClinicalTrials.gov registry entry for NCT00704431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-480848 (darapladib) is the first listed.
NCT00704431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00704431 about?
NCT00704431 is a clinical study titled "A Study With Darapladib to Collect Tolerability Information". Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and the remaining 9 days of dosing will occur at home. Subjects will record any adverse events throughout the dosing period in a paper diary. Subjects will return to the CRU 10-14 days after the last dose of da...
What is the current status of trial NCT00704431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-05. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00704431?
The interventions under investigation include: SB-480848 (darapladib) (DRUG).
Who is sponsoring clinical trial NCT00704431?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.